MicroRNA Therapeutic Advantage (why MUSC chose RNA over gene therapy)

**What it means:** The MUSC team evaluated multiple approaches (gene therapy, micro-RNA therapeutics) and chose the RNA-based approach because it "offered several advantages." These likely include: - **Reversibility:** RNA effects wear off when the drug clears, making it safer if there are unexpected side effects - **Manufacturing:** RNA therapeutics are generally easier and cheaper to manufacture than viral vectors - **Dosing flexibility:** RNA doses can be adjusted more easily than gene therapy (which is typically one-time) - **Regulatory familiarity:** RNA therapeutics have a longer regulatory track record than novel AAV gene therapies **Trade-off:** RNA therapeutics don't provide a permanent cure — patients would need ongoing treatment. Gene therapy offers the potential of a single "curative" dose, but with higher risk and regulatory complexity.